ClinicalTrials.gg
CompletedNCT02301143LAPACTUpdated Mar 20, 2019Results posted

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

A Phase 2 interventional study of nab-Paclitaxel and Gemcitabine in Pancreatic Neoplasms, sponsored by Celgene. Completed at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms — 22 open to participants now, 33 under way, 4 of them phase 3. Albumin-Bound Paclitaxel · Pancreatic Neoplasms.

Enrollment
30th of 130
107 · median 47
Started
2015
with 16 others
Phase 2
69 of 130
14 open now
Registered
35th of 130
by date
Lead sponsor
8 of 130
Celgene

Among the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, this one is the 30th largest by enrollment, is one of 17 that started in 2015, is one of 69 in phase 2, and was the 35th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

22 of the 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing Albumin-Bound Paclitaxel in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.

Read the detailed description

This is an international, non-randomized, open-label, multi-center, Phase 2 study in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. All subjects will be treated with nab-paclitaxel plus gemcitabine for 6 cycles followed by an Investigator's Choice of continuation of treatment with nab-paclitaxel plus gemcitabine, chemoradiation therapy, or surgery.

Safety assessments by laboratory testing and physical exams will be conducted through-out the study.

Efficacy assessments by physical exam will be preformed through-out the study and tumor imaging will be conducted approximately every 2 months.

Subjects will be considered active study participants from enrollment up to, but not including, survival follow-up period.

03

Conditions studied

  • Pancreatic Neoplasms

Keywords

  • Pancreatic Neoplasms
  • Pancreatic Cancer
  • Locally advanced pacriatic cancer
  • nab-Paclitaxel
  • Abraxane
  • Gemcitabine
  • ABI-007
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non- , unresectable, adenocarcinoma pancreatic cancer patients
  • No prior anticancer therapy for pancreatic cancer

    •≥ 18 years of age with a performance status of 0 or 1•Adequate complete blood counts, hepatic function, and renal function

  • Signed

Exclusion criteria

Exclusion Criteria:

  • Active bacterial, viral, or fungal infection
  • Infection with or C, or history of (HIV) infection, or receiving or myelosuppressive
  • Subjects with sensory neuropathy, ascites, or plastic biliary stent.
  • Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders (including but not limited to connective tissue disorders, lung disease, and cardiac or seizure disorders)
  • Women who are pregnant or breast feeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    nab-Paclitaxel plus Gemcitabine

    nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject. * Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR * Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR * Surgical intervention

    Drug: nab-Paclitaxel · Drug: Gemcitabine · Drug: Chemoradiation · Drug: Capecitabine · Procedure: Surgery

Interventions

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates for Time to Treatment Failure (TTF)

    TTF was defined as the time after the first dose of study therapy to discontinuation of study therapy due to disease progression, death by any cause, or the start of a new non-protocol-defined anticancer therapy/surgery. If a participant does not progress, die or start a new non-protocol-defined anticancer therapy, the participant was censored on the last tumor assessment date. Tumor evaluations of CT or MRI scans were assessed by the investigative sites and response determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. The definition for progressive disease (PD) was \>= 20% increase in the sum of diameters of target lesions from nadir, and the sum showed an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval (CI) of TTF were estimated using the method of Brookmeyer and Crowley.

    Time frame: Day 1 of study treatment up to 28.75 months; (maximum time for the last tumor assessment)

Secondary outcomes

  1. Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1

    DCR was defined as the percentage of participants with a CR or PR or SD from of date of first treatment to 16 weeks. Tumor assessments after start of non-protocol-defined anticancer therapy were excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. * SD: neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method.

    Time frame: Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks

  2. Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1

    ORR was defined as the percentage of participants that achieved a combined incidence of complete (CR) and partial response (PR) using RECIST 1.1 guidelines as assessed by the investigator. Assessments after new non-protocol-defined anticancer therapy are excluded. For participants who had resectable surgery in Investigator Choice period, assessments after surgical intervention are excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method

    Time frame: Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks

  3. Kaplan-Meier Estimate of Progression-Free Survival (PFS)

    Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free. The definition for progressive disease (PD) was at least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval of PFS were estimated using the method of Brookmeyer and Crowley.

    Time frame: Day 1 of study treatment up to 28.75 months (maximum time for the last tumor assessment)

  4. Kaplan-Meier Estimates for Overall Survival (OS)

    Overall survival was defined as the time from the date of first dose of study therapy to the date of death (by any cause). Participants who were alive at the end of study or clinical data cut were censored on the last known time that the participant was alive or the clinical cutoff date, whichever was earlier. Median and its 90% confidence interval of OS were estimated using the method of Brookmeyer and Crowley

    Time frame: Day 1 of study treatment up to 31.34 months (maximum time for survival follow-up)

  5. Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Global Health Status and 5 Functioning Scales

    The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 - 100 scale. In the Global Health Status and 5 functional scales, 0 = worst possible quality of life/health status and 100 = best possible quality of life/health status. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 increase from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 decrease from baseline

    Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit

  6. Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Symptom Scales and Single Symptom Items

    The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 to 100 scale. In the symptom scales and single symptom items, 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 decrease from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 increase from baseline

    Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit

  7. Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Six Summary Scales

    The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. All reported measures are transformed to a 0 to 100 scale. Six summary scales reported are: - Pancreatic Pain - Digestive Symptoms - Altered Bowel Habits - Hepatic Scale - Body Image - Sexuality Scores of 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation

    Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit

  8. Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Satisfaction With Health Care Scale

    The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The summary scale for Satisfaction with Health Care is reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = not satisfied, worst possible health state and 100 = extremely satisfied, best possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID increase from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID decrease from baseline MID = half the baseline standard deviation

    Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit

  9. Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): 10 Individual Item Scores

    The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The 10 individual item scores are reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = best possible health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation

    Time frame: Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit

  10. Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).

    Time frame: Day 1 of study drug up to end of the study; up to 31.3 months

07

Results

Posted Jan 8, 2019

Participant flow

Induction Period
Participant flow — Induction Period
MilestoneNab-Paclitaxel Plus GemcitabineInvestigator Choice
Started1070
Completed620
Not completed450
Withdrew: Enrolled but not treated10
Withdrew: Death10
Withdrew: Adverse event220
Withdrew: Progressive disease80
Withdrew: Withdrawal by subject30
Withdrew: Noncompliance with study drug10
Withdrew: Physician decision40
Withdrew: Symptomatic deterioration20
Withdrew: Protocol violation20
Withdrew: Other10
Investigator's Choice
Participant flow — Investigator's Choice
MilestoneNab-Paclitaxel Plus GemcitabineInvestigator Choice
Started047
Completed037
Not completed010
Withdrew: Adverse event03
Withdrew: Progressive disease03
Withdrew: Noncompliance with study drug01
Withdrew: Symptomatic deterioration01
Withdrew: Other01
Withdrew: Unresectable surgery01

Outcome measures

PrimaryKaplan-Meier Estimates for Time to Treatment Failure (TTF)

TTF was defined as the time after the first dose of study therapy to discontinuation of study therapy due to disease progression, death by any cause, or the start of a new non-protocol-defined anticancer therapy/surgery. If a participant does not progress, die or start a new non-protocol-defined anticancer therapy, the participant was censored on the last tumor assessment date. Tumor evaluations of CT or MRI scans were assessed by the investigative sites and response determined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. The definition for progressive disease (PD) was \>= 20% increase in the sum of diameters of target lesions from nadir, and the sum showed an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval (CI) of TTF were estimated using the method of Brookmeyer and Crowley.

Time frame:
Day 1 of study treatment up to 28.75 months; (maximum time for the last tumor assessment)
Reported as:
Median · months
Kaplan-Meier Estimates for Time to Treatment Failure (TTF)
monthsNab-Paclitaxel Plus Gemcitabine
Kaplan-Meier Estimates for Time to Treatment Failure (TTF)9.0 (7.26 to 10.05)
SecondaryDisease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1

DCR was defined as the percentage of participants with a CR or PR or SD from of date of first treatment to 16 weeks. Tumor assessments after start of non-protocol-defined anticancer therapy were excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. * SD: neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method.

Time frame:
Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks
Reported as:
Number · percentage of participants
Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.1
percentage of participantsNab-Paclitaxel Plus Gemcitabine
Disease Control Rate (DCR): Percentage of Participants With Complete (CR) or Partial Response (PR), or Stable Disease (SD) for ≥ 16 Weeks According to RECIST Version 1.177.6 (70.3 to 83.5)
SecondaryOverall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1

ORR was defined as the percentage of participants that achieved a combined incidence of complete (CR) and partial response (PR) using RECIST 1.1 guidelines as assessed by the investigator. Assessments after new non-protocol-defined anticancer therapy are excluded. For participants who had resectable surgery in Investigator Choice period, assessments after surgical intervention are excluded. RECIST 1.1 Definition: * CR: disappearance of all target and non-target lesions; any pathological lymph nodes (target or non-target) must have reduction in short axis to \< 10 mm and no new lesions diagnosed. * PR: a \>= 30% decrease in the sum of diameters of target lesions from baseline; no evidence of progression in any of the non-target lesions diagnosed at baseline; and no new lesions diagnosed. The two-sided 90% binomial confidence intervals (CIs) were estimated by Wilson score method

Time frame:
Day 1 of study treatment up to the end of investigator choice period plus 28 days; up to 76.9 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.1
percentage of participantsNab-Paclitaxel Plus Gemcitabine
Overall Response Rate (ORR): Percentage of Participants With Complete (CR) or Partial Response (PR) According to RECIST Version 1.139.3 (31.8 to 47.2)
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS)

Progression-free Survival (PFS) was defined as the time from the date of the first dose to the date of disease progression or death (by any cause), whichever is earlier. The analysis day was calculated from enrollment date for one participant who was not treated. Participants who have no disease progression or have not died were censored to last tumor assessment date with progression-free. The definition for progressive disease (PD) was at least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of \>= 5 mm; the progression of a non-target lesion or the appearance of any new lesions is also considered progression. Median and its 90% confidence interval of PFS were estimated using the method of Brookmeyer and Crowley.

Time frame:
Day 1 of study treatment up to 28.75 months (maximum time for the last tumor assessment)
Reported as:
Median · months
Kaplan-Meier Estimate of Progression-Free Survival (PFS)
monthsNab-Paclitaxel Plus Gemcitabine
Kaplan-Meier Estimate of Progression-Free Survival (PFS)10.9 (9.26 to 11.63)
SecondaryKaplan-Meier Estimates for Overall Survival (OS)

Overall survival was defined as the time from the date of first dose of study therapy to the date of death (by any cause). Participants who were alive at the end of study or clinical data cut were censored on the last known time that the participant was alive or the clinical cutoff date, whichever was earlier. Median and its 90% confidence interval of OS were estimated using the method of Brookmeyer and Crowley

Time frame:
Day 1 of study treatment up to 31.34 months (maximum time for survival follow-up)
Reported as:
Median · months
Kaplan-Meier Estimates for Overall Survival (OS)
monthsNab-Paclitaxel Plus Gemcitabine
Kaplan-Meier Estimates for Overall Survival (OS)18.8 (14.95 to 24.02)
SecondaryParticipant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Global Health Status and 5 Functioning Scales

The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 - 100 scale. In the Global Health Status and 5 functional scales, 0 = worst possible quality of life/health status and 100 = best possible quality of life/health status. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 increase from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 decrease from baseline

Time frame:
Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Reported as:
Count of participants · Participants
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Global Health Status and 5 Functioning Scales
ParticipantsNab-Paclitaxel Plus Gemcitabine
Global Health Status: Improved43
Global Health Status: Stable34
Global Health Status: Worsened18
Physical Functioning Scale: Improved20
Physical Functioning Scale: Stable66
Physical Functioning Scale: Worsened9
Role Functioning Scale: Improved36
Role Functioning Scale: Stable46
Role Functioning Scale: Worsened13
Emotional Functioning Scale: Improved50
Emotional Functioning Scale: Stable40
Emotional Functioning Scale: Worsened5
Cognitive Functioning Scale: Improved33
Cognitive Functioning Scale: Stable51
Cognitive Functioning Scale: Worsened11
Social Functioning Scale: Improved38
Social Functioning Scale: Stable43
Social Functioning Scale: Worsened14
SecondaryParticipant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Symptom Scales and Single Symptom Items

The European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30) is a validated health-related quality of life (HRQoL) measure. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures, including 5 functional scales, 3 symptom scales, 6 single symptom items, and 1 global health status / quality of life scale. No item occurs in more than one scale. All reported measures are transformed to a 0 to 100 scale. In the symptom scales and single symptom items, 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=10 decrease from baseline - Stable: neither increase nor decrease \>10 - Worsened: \>=10 increase from baseline

Time frame:
Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Reported as:
Count of participants · Participants
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Symptom Scales and Single Symptom Items
ParticipantsNab-Paclitaxel Plus Gemcitabine
Symptom Scale-Fatigue: Improved46
Symptom Scale-Fatigue: Stable24
Symptom Scale-Fatigue: Worsened25
Scale-Nausea+Vomiting: Improved29
Scale-Nausea+Vomiting: Stable64
Scale-Nausea+Vomiting: Worsened2
Symptom Scale-Pain: Improved62
Symptom Scale-Pain: Stable29
Symptom Scale-Pain: Worsened4
Symptom - Dyspnoea: Improved12
Symptom - Dyspnoea: Stable74
Symptom - Dyspnoea: Worsened9
Symptom - Insomnia: Improved53
Symptom - Insomnia: Stable35
Symptom - Insomnia: Worsened7
Symptom - Appetite loss: Improved48
Symptom - Appetite loss: Stable39
Symptom - Appetite loss: Worsened8
Symptom - Constipation: Improved46
Symptom - Constipation: Stable45
Symptom - Constipation: Worsened4
Symptom - Diarrhoea: Improved18
Symptom - Diarrhoea: Stable69
Symptom - Diarrhoea: Worsened8
Symptom - Financial difficulties: Improved17
Symptom - Financial difficulties: stable:74
Symptom - Financial difficulties: Worsened4
SecondaryParticipant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Six Summary Scales

The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. All reported measures are transformed to a 0 to 100 scale. Six summary scales reported are: - Pancreatic Pain - Digestive Symptoms - Altered Bowel Habits - Hepatic Scale - Body Image - Sexuality Scores of 0 = optimal health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation

Time frame:
Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Reported as:
Count of participants · Participants
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Six Summary Scales
ParticipantsNab-Paclitaxel Plus Gemcitabine
Pancreatic Pain Scale: Improved62
Pancreatic Pain Scale: Stable33
Pancreatic Pain Scale: Worsened0
Digestive Symptom Scale: Improved49
Digestive Symptom Scale: Stable36
Digestive Symptom Scale: Worsened10
Altered Bowel Habits Scale: Improved28
Altered Bowel Habits Scale: Stable53
Altered Bowel Habits Scale: Worsened14
Hepatic Scale: Improved25
Hepatic Scale: Stable66
Hepatic Scale: Worsened4
Body Image Scale: Improved22
Body Image Scale: Stable50
Body Image Scale: Worsened23
Sexuality Scale: Improved31
Sexuality Scale: Stable51
Sexuality Scale: Worsened13
SecondaryParticipant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Satisfaction With Health Care Scale

The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The summary scale for Satisfaction with Health Care is reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = not satisfied, worst possible health state and 100 = extremely satisfied, best possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID increase from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID decrease from baseline MID = half the baseline standard deviation

Time frame:
Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Reported as:
Count of participants · Participants
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): Satisfaction With Health Care Scale
ParticipantsNab-Paclitaxel Plus Gemcitabine
Satisfaction with Health Care Scale: Improved42
Satisfaction with Health Care Scale: Stable40
Satisfaction with Health Care Scale: Worsened13
SecondaryParticipant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): 10 Individual Item Scores

The EORTC pancreatic cancer module is a validated tool intended for patients at all disease stages undergoing surgical resection, palliative surgical intervention, endoscopic palliation or palliative chemotherapy. The module includes 26 questions, organized into 7 scales and 10 individual item scores. The 10 individual item scores are reported. All reported measures are transformed to a 0 to 100 scale. Scores of 0 = best possible health state and 100 = worst possible health state. The best score on treatment is the best score from all post-baseline visits and is compared to the baseline to get the following responder categories. Responder categories: - Improved: \>=MID decrease from baseline - Stable: no increase or decrease \>MID - Worsened: \>=MID increase from baseline MID = half the baseline standard deviation

Time frame:
Baseline (Day -1), Day 1 of each cycle, for up to 19 cycles each cycle consisting of 28 days and the 28-day follow-up visit
Reported as:
Count of participants · Participants
Participant Counts in Response Categories Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire For Pancreatic Cancer (EORTC-QLQ PAN26): 10 Individual Item Scores
ParticipantsNab-Paclitaxel Plus Gemcitabine
Abdominal Bloating: Improved50
Abdominal Bloating: Stable42
Abdominal Bloating: Worsened3
Taste Changes: Improved20
Taste Changes: Stable54
Taste Changes: Worsened21
Indigestion: Improved41
Indigestion: Stable47
Indigestion: Worsened7
Flatulence: Improved47
Flatulence: Stable37
Flatulence: Worsened11
Weight Loss: Improved36
Weight Loss: Stable56
Weight Loss: Worsened3
Limb Weakness: Improved22
Limb Weakness: Stable55
Limb Weakness: Worsened18
Dry Mouth: Improved37
Dry Mouth: Stable45
Dry Mouth: Worsened13
Treatment Side-Effects: Improved8
Treatment Side-Effects: Stable48
Treatment Side-Effects: Worsened39
Worry About Future Health: Improved42
Worry About Future Health: Stable45
Worry About Future Health: Worsened8
Limits on Activity Planning: Improved42
Limits on Activity Planning: Stable42
Limits on Activity Planning: Worsened11
SecondaryParticipants With Treatment Emergent Adverse Events (TEAEs)

TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).

Time frame:
Day 1 of study drug up to end of the study; up to 31.3 months
Reported as:
Count of participants · Participants
Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsNab-Paclitaxel Plus Gemcitabine (Induction Period)Nab-Paclitaxel Plus Gemcitabine (Overall)
>= 1 TEAE105105
>=1 related TEAE102103
>=1 TEAE of severity grade 3 or higher8590
>=1 related TEAE of severity grade 3 or higher7275
>=1 serious TEAE3839
>= 1 related serious TEAE1414
>=1 TEAE leading to discontinuation of IP2528
>=1 related TEAE leading to discontinuation of IP1518
>=1 TEAE leading to dose reduction of IP6972
>=1 related TEAE leading to dose reduction of IP6871
>=1 TEAE leading to interruption of IP6668
>=1 related TEAE leading to interruption of IP4850
>= TEAE leading to death22
>=1 related TEAE leading to death00

Adverse events

Collected over Day 1 of study drug up to end of the study; up to 31.3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nab-Paclitaxel Plus Gemcitabine (Induction Period)42/106 (39.6%)38/106 (35.8%)104/106 (98.1%)
Nab-Paclitaxel Plus Gemcitabine (Overall)67/106 (63.2%)39/106 (36.8%)104/106 (98.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventNab-Paclitaxel Plus Gemcitabine (Induction Period)Nab-Paclitaxel Plus Gemcitabine (Overall)
PyrexiaGeneral disorders5/1065/106
PneumoniaInfections and infestations5/1065/106
Febrile neutropeniaBlood and lymphatic system disorders3/1063/106
Atrial fibrillationCardiac disorders2/1062/106
Abdominal painGastrointestinal disorders2/1062/106
CellulitisInfections and infestations2/1062/106
Neutropenic sepsisInfections and infestations2/1062/106
SepsisInfections and infestations2/1062/106
Blood bilirubin increasedInvestigations1/1061/106
DehydrationMetabolism and nutrition disorders1/1061/106
Most frequent other events
Showing 10 of 62
Most frequent other events
EventNab-Paclitaxel Plus Gemcitabine (Induction Period)Nab-Paclitaxel Plus Gemcitabine (Overall)
AlopeciaSkin and subcutaneous tissue disorders57/10657/106
FatigueGeneral disorders53/10653/106
AnaemiaBlood and lymphatic system disorders49/10649/106
DiarrhoeaGastrointestinal disorders48/10648/106
NauseaGastrointestinal disorders46/10647/106
Oedema peripheralGeneral disorders45/10647/106
Decreased appetiteMetabolism and nutrition disorders46/10646/106
NeutropeniaBlood and lymphatic system disorders44/10645/106
PyrexiaGeneral disorders39/10640/106
AstheniaGeneral disorders36/10636/106

Baseline characteristics

Intent-to-treat (ITT) population at start of Induction

Age, Continuous
Age, Continuous(years)Nab-Paclitaxel Plus Gemcitabine
Median65.0 (42 to 85)
Age, Customized
Age, Customized(Participants)Nab-Paclitaxel Plus Gemcitabine
<65 years44
>=65 - 75 years50
>75 years13
Sex: Female, Male
Sex: Female, Male(Participants)Nab-Paclitaxel Plus Gemcitabine
Female59
Male48
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nab-Paclitaxel Plus Gemcitabine
Hispanic or Latino1
Not Hispanic or Latino78
Unknown or Not Reported28
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nab-Paclitaxel Plus Gemcitabine
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American2
White72
More than one race0
Unknown or Not Reported30
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Nab-Paclitaxel Plus Gemcitabine
Grade 050
Grade 157
Grade 20
Grade 30
Grade 40
Physician Assessment of Peripheral Neuropathy
Physician Assessment of Peripheral Neuropathy(Participants)Nab-Paclitaxel Plus Gemcitabine
Grade 0101
Grade 16
Grade 20
Grade 30
Grade 40
Baseline Albumin
Baseline Albumin(g/L)Nab-Paclitaxel Plus Gemcitabine
Median39.0 (28 to 50)

5 further baseline measures are reported on the registry.

08

Study locations

42 sites
  • Mayo Clinic - Arizona
    Scottsdale, Arizona 85259, United States
  • UC Davis Cancer Center
    Sacramento, California 95817, United States
  • Scripps Clinic Torrey Pines
    San Diego, California 92037, United States
  • Smilow Cancer Hospital At Yale-New Haven
    New Haven, Connecticut 06510, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20007, United States
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
  • Piedmont Cancer Institute PC
    Atlanta, Georgia 30318, United States
  • Cancer Treatment Centers of America - Southeastern Regional Medical Center
    Newnan, Georgia 30265, United States
  • ME Center for Cancer Medicine
    Scarborough, Maine 04074, United States
  • Tufts - New England Medical Center
    Boston, Massachusetts 02111, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • Saint Joseph Mercy Ann Arbor Hospital
    Ann Arbor, Michigan 48106, United States
  • Karmanos Cancer Center Wayne State University
    Detroit, Michigan 48201, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Regional Cancer Care Associates LLC
    Morristown, New Jersey 07962, United States
  • Montefiore Einstein Cancer Center
    Bronx, New York 10461, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Clinical Research Alliance
    Lake Success, New York 11042, United States
  • State University of New York Upstate Medical Center
    Syracuse, New York 13215, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Mark H Zangmeister Center
    Columbus, Ohio 43219, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5505, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • CHUM Hôpital Saint-Luc
    Montreal, Quebec H2L 4M1, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
  • Centre Regional de lutte contre le cancer Paul Papin
    Angers, 49933, France
  • CHRU Besancon
    Besançon, 25000, France
  • Centre Hospitalier Belfort Montbeliard
    Besançon, France
  • Hopital Beaujon
    Clichy cedex, France
  • Hopital Saint Antoine
    Paris, 75012, France
  • Hopital Haut Leveque
    Pessac Cedex, 33604, France
  • Ospedale Sacro Cuore di Gesu FatebeneFratelli
    Benevento, 82100, Italy
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Policlinico Universitario Campus Biomedico Di Roma
    Roma, 128, Italy
  • Hospital Universitario a Coruna
    A Coruna, 15006, Spain
  • ICO-Hospital Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Publications

  • Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, Lopez-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):285-294. doi: 10.1016/S2468-1253(19)30327-9. Epub 2020 Jan 14. PubMed 31953079 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Nov 2017, 31 months.

Results were first posted in Jan 2019, 1 year 1 month after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 31 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2014
First posted
Nov 25, 2014
StartActual
Apr 21, 2015
Primary completionActual
Nov 21, 2017
CompletionActual
Apr 26, 2018
Results first posted
Jan 8, 2019
Last update
Mar 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02301143
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 25, 2014
Start date
Apr 21, 2015
Primary completion
Nov 21, 2017
Completion
Apr 26, 2018
Results posted
Jan 8, 2019
Last update
Mar 20, 2019

Study contacts

Teng Jin Ong, MD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion